Fresenius SE & Co. (OTCMKTS:FSNUY) Hits New 12-Month High – Still a Buy?

Shares of Fresenius SE & Co. (OTCMKTS:FSNUY) hit a new 52-week high on Wednesday . The company traded as high as $14.75 and last traded at $14.55, with a volume of 80762 shares trading hands. The stock had previously closed at $14.13.

Analysts Set New Price Targets

Separately, Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. in a research report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy”.

Fresenius SE & Co. Stock Up 3.0%

The stock has a market capitalization of $32.50 billion, a price-to-earnings ratio of 27.45 and a beta of 0.83. The company has a quick ratio of 1.00, a current ratio of 1.31 and a debt-to-equity ratio of 0.49. The business’s 50-day moving average is $13.83 and its two-hundred day moving average is $12.65.

Fresenius SE & Co. (OTCMKTS:FSNUY) last issued its earnings results on Wednesday, August 6th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.02. The company had revenue of $6.48 billion during the quarter, compared to analysts’ expectations of $5.83 billion. Fresenius SE & Co. had a return on equity of 9.33% and a net margin of 5.09%. Equities analysts anticipate that Fresenius SE & Co. will post 0.79 EPS for the current year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.